Brief: Intensity Therapeutics Q2 Operating Income USD -3.084 Million
Intensity Therapeutics Q1 net loss narrows on lower R&D costs
Brief: Intensity Therapeutics Q1 Operating Income USD -2.526 Million
Brief: Intensity Therapeutics Inc - Increases ATM Offering Capacity To $60 Million On March 23, 2026 - SEC Filing
U.S. STOCKS ON THE MOVE -Gyre Therapeutics, Nutrien Ltd, Rapid Micro Biosystems
U.S. STOCKS ON THE MOVE -Natera, Pacira BioSciences, Kezar Life Sciences
U.S. STOCKS ON THE MOVE-SciSparc, Natera, US energy companies
Intensity Therapeutics rises as breast cancer drug shows early promise
Brief: Intensity Therapeutics Regains Compliance With Nasdaq's Minimum Bid Price Requirement
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Intensity Therapeutics Announces Reverse Stock Split
Brief: Intensity Therapeutics Highlights 2025 Milestones And Outlines 2026 Strategic Priorities
U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companies
U.S. STOCKS ON THE MOVE-Praxis, EUDA Health, Humana
U.S. STOCKS ON THE MOVE-Warner Bros Discovery, Ulta Beauty, Victoria's Secret
Intensity Therapeutics jumps after Nasdaq grants compliance extension
Brief: Intensity Therapeutics Granted 180-Day Extension